China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022, there are eight approved biosimilars of Roche’s Avastin (bevacizumab), six of AbbVie’s Humira (adalimumab), and three of J&J’s Remicade (infliximab), with many more in development. China has a high disease burden of cancer and immunological diseases, and the country bears the highest global footprint of many such illnesses. The approval of cost-effective biosimilars has boosted the uptake of biologics in the respective markets. Various regulatory policies are being implemented to streamline the overall drug development, approval, and reimbursement processes, further encouraging adoption of biosimilars in China market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by nine thought-leader experts with extensive experience in pricing, reimbursement, health economics, and pharmaceutical management in China and surveys with 75 medical oncologists and immunologists / rheumatologists
10-year, annualized sales and patient share of key biosimilars in oncology and immunology through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 20+ biosimilars.